eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2020
vol. 45
 
Share:
Share:
more
 
 
abstract:
Experimental immunology

CCR6 blockade on regulatory T cells ameliorates experimental model of multiple sclerosis

Izabela Jatczak-Pawlik
1
,
Paweł Wolinski
1
,
Dominika Książek-Winiarek
2
,
Mirosława Pietruczuk
3
,
Andrzej Glabinski
1, 2

1.
Department of Propedeutics of Neurology, Medical University of Lodz, Poland
2.
Department of Neurology and Stroke, Medical University of Lodz, Poland
3.
Department of Laboratory Medicine, Medical University of Lodz, Poland
Cent Eur J Immunol 2020; 45 (3): 256-266
Online publish date: 2020/11/01
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Regulatory T cells (Tregs) play a significant role in limiting damage of tissue affected by autoimmune process, which has been demonstrated in various experimental models for multiple sclerosis (MS) (mostly experimental autoimmune encephalomyelitis – EAE), rheumatoid arthritis, and type 1 diabetes. In this study, we demonstrated that Tregs increasingly migrate to central nervous system (CNS) during subsequent phases of EAE (preclinical, initial attack, and remission). In contrast, in peripheral tissues (blood, lymph nodes, and spleen), a significant accumulation of Tregs is mostly present during EAE remission. Moreover, an increased expression of CCR6 on Tregs in the CNS, blood, lymph nodes, and spleen in all phases of EAE was observed. The highest expression of CCR6 on Tregs from the CNS, lymph nodes, and spleen was noted during the initial attack of EAE, whereas in the blood, the peak expression of CCR6 was detected during the preclinical phase. The presence of Tregs in the CNS during EAE was confirmed by immunohistochemistry. To analyze additional functional significance of CCR6 expression on Tregs for EAE pathology, we modulated the clinical course of this MS model using Tregs with blocked CCR6. EAE mice, which received CCR6-deficient Tregs showed significant amelioration of disease severity. This observation suggests that CCR6 on Tregs may be a potential target for future therapeutic interventions in MS.
keywords:

multiple sclerosis, Tregs, CCR6, experimental autoimmune encephalomyelitis, anti-CCR6

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe